A B S T R A C T Evidence for the presence of immune complexes in blood, synovial fluid, and tissues of patients with rheumatoid arthritis (RA) includes low complement levels in blood and effusions, deposition of immunoreactants in tissues and vessel walls, and precipitate formation after addition of monoclonal rheumatoid factor (mRF) to (1) (2) (3) (4) (5) (6) (7) . Winchester, Agnello, and Kunkel have shown a close correlation between the presence of this material in synovial fluid and low levels of complement (4) . These high molecular weight complexes may well play a significant role in the chronic inflammatory process that characterizes this disease. However, the precise role of these presumed complexes in RA is still not known. One significant limitation to learning more about the nature of this material and its relationship to the clinical features of RA has been the lack of a sensitive, easily performed, and reproducible quantitative method for measuring it. Winchester et al. (4) measured the amount of material in synovial fluid precipitable with monoclonal rheumatoid factor (mRF) by the quantitative precipitin test but this method is cumbersome and requires relatively large amounts of the reagent, mRF.
These same authors (5) have also reported the use of monoclonal rheumatoid factors in double immunodiffusion for demonstrating these immune complexes in rheumatoid sera and synovial fluids. Although useful in detecting this material, the technique is not quantitative, and weak precipitin reactions are hard to read with confidence. As a result, we have developed a solid-phase radioimmunoassay (8) (10) . The aggregates were dissolved in neutral buffer, applied to a 5-40% sucrose density gradient, and centrifuged at 283,000 g (bottom of the tubes) for 6 h in an International B-60 ultracentrifuge in a SW 283 rotor (40,000 rpm) (Damon/IEC, Needham Heights, Mass.). Tubes containing aggregates of approximately 25S were pooled and used in subsequent studies. Aggregated IgG was radiolabeled with 'I by the method of Hunter and Greenwood (11) . We mixed 2.0 mg of agg IgG in 5.0 ml of 0.1 M Tris, 0.2 M NaC1, pH 8.0, buffer with 0.56 mCi of carrier-free =2I with constant stirring. Then 0.5 mg of chloramine-T in 0.1 ml of pH 7.0 phosphatebuffered saline was added, and exactly 1 min later 0.25 mg of sodium metabisulphite in 0.1 ml of phosphate-buffered saline. The mixture was passed through a 1 X 25-cm Sephadex G-25 column, and the tubes containing the first radioactive peak were pooled. The specific activity of most preparations was about 0.2 mCi/mg. (Fig. 3) . At the equivalence point, 0.125 mg/ml of hemocyanin, as determined by examining the supernates in double immunodiffusion (17) Reproducibility of immunoassay and effects of heating and freezing sera. 14 sera containing 1 to more than 150 lsg agg IgG eq/ml were assayed several times. Of these, two were assayed seven times each and the variation in the results was less than 5%. 10 sera were assayed twice with less than 5% difference between the individual samples in each pair. Two additional sera gave results which varied significantly. One, assayed twice, showed results of 1 and 25 Ihg/ml of agg IgG equivalent and the other yielded results of 50, 68, and 11 Ag of agg IgG eq/ml on different occasions.
Heating sera at 56°C for 60 min to inactivate complement resulted in the appearance of inhibitory activity, probably resulting from the formation of aggregates. Therefore, all sera and fluids were used without heating.
Freezing at -20°C and thawing sera seven times did not result in any change in the amount of reacting material, as compared with that of samples stored at 4°C. Thus use of sera and synovial fluids stored at -70°C and thawed two to three times did not affect the results.
Density gradient ultracentrifugation. In order to estimate the size of reacting material, rheumatoid sera found to contain material reacting in the assay were applied to 5-30% sucrose density gradients and the fractions assayed by immunoassay. Fig. 5a and b dem- IgG eq/ml, 11 of these patients was seropositive, and all twelve had definite or classical RA. For statistical analyses, the rheumatoid patients were divided into two groups: one, patients whose sera contained 25 Ag agg IgG eq/ml or less, and two, patients whose sera contained more than 25 eg agg IgG eq/ml. The duration of disease for the two groups was found to be longer in the patients with immune complexes at P = 0.05 level, by a two-sided rank sum test. An association between severity of disease as measured by functional class (Fig. 7) and anatomical stage (Fig. 8 sions of undetermined etiology, and one each of pseudogout, psoriasis, ankylosing spondylitis, and intermittent hydroarthrosis (Fig. 9) . We were not able to establish a statistically significant relationship between C4 and agg IgG in rheumatoid synovial fluids by Spearman's rank correlation coefficient, as had been possible for serum. A two-sided rank sum test did reveal that mean complement levels were significantly lower in fluids containing immune complexes (P = 0.05). Fig. 9 shows results of comparing paired sera and synovial fluids in rheumatoid and miscellaneous disease patients. Four rheumatoid synovial fluids contained significant amounts of agg IgG activity and each contained more than was present in the corresponding serum. Thus it appears unlikely that the synovial fluid material represented only transport of immune complex material from the serum.
DISCUSSION
In the last few years both direct and indirect evidence has accumulated for the presence of immune complexes in patients with RA. Fish, Michael, Gewurz, and Good (18) (20) found similar deposits in the walls of nutrient vessels of sural nerves of patients with rheumatoid neuropathy. Previously Pekin and Zvaifler (21, 22) and Hedberg (23) had reported disproportionately low levels of hemolytic complement in the synovial fluids as compared to the sera in patients with RA. Subsequently, Franco and Schur (24) and Hunder Baumal and Broder (7), who isolated high molecular weight material by G-200 Sephadex chromatography from rheumatoid sera that was capable of initiating a complementdependent reaction resulting in release of histamine from guinea pig lung. This material, rheumatoid biologically active factor (RBAF), was found in both sera and synovial fluids. Subsequently, the presence of RBAF was found to correlate with disease activity (26) and to disappear as a result of successful treatment (27, 28) .
A simpler technique for demonstration of immune complexes was introduced in 1967 by Hannestad (3) . He found that certain high-titer RFs, capable of precipitating agg IgG, produced precipitin reactions with certain rheumatoid synovial fluids. Winchester, Kunkel, and Agnello (5) reported that mRFs were superior reagents for demonstrating such material. These workers isolated the reactive material and showed that it contained IgG, some of which represented IgG RF. Whether we are also detecting additional antigen-antibody systems that may be relevant to the pathogenesis of RA is still unknown. The lack of close correlation between RF titer and the amount of immune complexlike material present in rheumatoid sera favors the presence of such other systems, as do other observations in our laboratory showing a lack of relationship between RF content and complement-fixing activity of rheumatoid sera (30) .
The frequency of positive reactions in the sera of our rheumatoid patients (26%) was somewhat less than in the group of patients reported by Winchester et al. (50%) (5) . Without more data on the populations of patients studied, our lower percentage of abnormal results cannot be explained. The correlation between the presence of immune complex-like material in sera and indices of disease severity as well as low serum complement suggests that it may be related in some way to the disease process. It does not appear to be identical with the RBAF described by Baumal and Broder (7) . Measurements performed on 20 sera and 20 synovial fluids, on which assays for RBAF had been performed in their laboratory, did not show a close relationship between the presence of RBAF and agg IgG equivalent.
The low levels of immune complex-like material in the sera of patients with SLE, only 2 of 29 (7%), were at first somewhat surprising, in view of the evidence that SLE is an immune complex disease. However, Winchester et al. (5) found that only 8% of sera from patients with hypocomplementemic SLE showed such precipitin reactions. Clq, which detects complexes in SLE sera but not in RA sera (31) , and RFs appear to measure different types of immune complexes. Size of the complexes present may be an important determinant in reactivity with these two reagents. Winchester et al. (5) 
